• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    11/1/24 4:00:34 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care
    Get the next $BDMD alert in real time by email
    6-K 1 tm2427285d1_6k.htm FORM 6-K

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER 

    PURSUANT TO RULE 13a-16 OR 15d-16 

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2024 

    Commission File Number 001-42300

     

    Baird Medical Investment Holdings
    Limited

     

    Room 202, 2/F, Baide Building, Building 11, No.15
    Rongtong Street, Yuexiu District, Guangzhou,
     

    Peoples Republic of China 

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

     

     

     

     

    Explanatory Note

     

    This current report on Form 6-K is furnished in connection with the resignation of Mr. Kun Seng Ng from the position of the chief financial officer and company secretary of Baird Medical Investment Holdings Limited (the “Company”) for personal reasons, which did not result from any disagreement with the Company on any matters relating to the Company’s operations, policies or practice. Ms. Jie Li will serve as the acting chief financial officer of the Company following Mr. Kun Seng Ng’s resignation, effective from November 1, 2024.

     

    Ms. Jie Li has served as the Company’s reporting director since May 2024. Prior to joining the Company, Ms. Li gained extensive experience from “Big Four” PRC-based accounting firms from 2010 to 2017 and had served as an audit manager since 2015. After that, Ms Li had more than five-year working experience in U.S. listed companies where she was in charge of the public companies’ overall financial reporting and internal control over financial reporting. Ms. Li received a bachelor’s degree in management accounting from Capital University of Economics and Business in 2010. Ms. Li has been a member of the Chinese Institute of Certified Public Accountants since 2019 and obtained the qualification of Association of Chartered Certified Accountants in 2015.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: November 1, 2024

     

      By: /s/ Haimei Wu
      Name: Haimei Wu
      Title: Chairwoman and Chief Executive Officer

     

     

     

    Get the next $BDMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BDMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

    NEW YORK, March 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company's goal to expand patient access to advanced, minimally invasive treatment options. Baird Medical's proprietary MWA platforms garnered significant interest during the event's thermal ablation worksho

    3/9/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Accelerates Global Registration of AI-Driven Surgical Software

    NEW YORK, March 4, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of development for its cross-platform surgical software, officially commencing the registration process in the United States, the European Union, and China. Leveraging a proprietary artificial intelligence model, the system automates core clinical workflows, including anatomical mapping, dynamic treatment planning, and procedural simulations. By integrat

    3/4/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Accelerates U.S. Expansion at NASOIE 2026

    NEW YORK, March 2, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies.

    3/2/26 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    SEC Filings

    View All

    SEC Form S-8 filed by Baird Medical Investment Holdings Ltd

    S-8 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    3/10/26 8:43:55 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    6-K - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    2/10/26 7:59:47 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Baird Medical Investment Holdings Ltd

    424B3 - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    1/16/26 4:32:46 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    Leadership Updates

    Live Leadership Updates

    View All

    Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion

    NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the appointment of Mark Saxton as Chief Executive Officer of its U.S. subsidiary. Mr. Saxton is a seasoned medical device executive with more than 25 years of commercial leadership experience, including a decade advancing intravascular RF ablation technologies. He will lead all U.S. operations, including sales, marketing, and market development, as Baird Medical

    12/3/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025. Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share

    10/20/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care